Event-free and overall survival. (A) The 2-year event-free survival probabilities after nonmyeloablative haploidentical bone marrow transplantation with thiotepa and posttransplant cyclophosphamide were significantly higher in adults than in children with SCD. The event-free survival probabilities at 2 years for children and adults were 68.4% (95% CI: 49.1-81.6) and 94.7% (95% CI: 80.6-98.7), respectively. (B) The 2-year overall survival probabilities after nonmyeloablative haploidentical bone marrow transplantation with thiotepa and posttransplant cyclophosphamide were comparable between adults and children with SCD. The overall survival probabilities at 2 years for children and adults were 93.6% (95% CI: 76.9-98.3) and 94.7% (95% CI: 80.6-98.7), respectively.